Psychometric properties of two new measures of quality of life (QoL) and treatment satisfaction in hypothyroidism: the THYDQoL and THYTSQ [Abstract 1080] by McMillan, C et al.
McMillan CV, Bradley C, Razvi S and Weaver JU (2005) Psychometric validation of new 
measures of hypothyroid-dependent quality of life (QoL) and symptoms. 24th Joint Meeting 
of the British Endocrine Societies, Endocrine Abstracts 9 Abstract P151. 
 
http://www.endocrine-abstracts.org/ea/0009/ea0009p151.htm 
http://digirep.rhul.ac.uk/items/558c75a6-5730-1020-7d48-70ecdc46f0b2/1/ 
 
Abstract presented as a poster at the British Endocrine Societies 24th Joint Meeting.  4-6 
April, 2005.  Harrogate. 
 
Psychometric validation of new measures of hypothyroid-dependent 
quality of life (QoL) and symptoms  
 
CV McMillan1, C Bradley1, S Razvi2, JU Weaver2,3 
1Department of Psychology, Royal Holloway, University of London, Egham, UK. 
2Department of Diabetes and Endocrinology, Queen Elizabeth Hospital, Gateshead, UK. 
3School of Clinical Medical Sciences, University of Newcastle upon Tyne, Gateshead UK. 
 
Objective: To evaluate the psychometric properties of two new condition-specific 
questionnaires: (1) the 18-item ThyDQoL, an individualised patient-centred measure of 
perceived impact of hypothyroidism on QoL, and (2) the 15-item ThySC symptom checklist 
in which patients provide “bother” ratings for common hypothyroid symptoms. 
 
Method: A cross-sectional survey was conducted with 110 adults with clinical or subclinical 
hypothyroidism [mean age: 55.1 plus/minus 14.3 (s.d.), range 23–84 years], 103 treated 
with thyroxine. Respondents rated personally applicable ThyDQoL life domains for 
importance and impact of their hypothyroidism, and rated ThySC symptoms for bother. 
Ethical committee approval was obtained. 
 
Results: High completion rates (>98%) indicated the measures’ acceptability to 
respondents. All 18 ThyDQoL domains were, on average, rated negatively impacted by 
hypothyroidism and important for QoL.  Psychometric analyses indicated that applicable 
ThyDQoL domains could be summed into an overall Average Weighted Impact score 
(AWI), for which the sample mean (-3.1 plus/minus 2.2) indicated considerable negative 
impact of hypothyroidism on QoL (maximum possible range -9 to +3). The most frequently 
reported ThySC symptoms were tiredness (90% of sample), depression (73%), skin 
problems (60%), and weight gain (59%). Highest bother ratings were: hair problems (2.3 
plus/minus 0.9), weight gain (2.2 plus/minus 0.9), and depression (2.1 plus/minus 0.8), 
(maximum possible range: 0 to 3, from “not at all” to “very much bothered”). Correlations 
between ThySC bother ratings and equivalent or near equivalent ThyDQoL domains 
(energy, weight, bodily discomfort and depression) ranged from -0.4 to -0.43, (p<0.05). The 
strongest correlation between any individual symptom bother rating and ThyDQoL AWI was 
for tiredness, -0.61, p<0.001.  
  
Conclusion: Although measures of hypothyroid symptoms are often and erroneously 
described as QoL measures, symptoms and QoL are distinct and separate patient-reported 
outcomes. The new ThyDQoL and ThySC questionnaires will be valuable in routine clinical 
monitoring and clinical trials of treatments for hypothyroidism. 
 
 
